{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.536","upperLimit":"0.761","value":"0.662"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Kaplan-Meier estimate at three years post-first transplant of survival. Outcome is death or alive at follow-up (censored). 95 percent confidence interval of the point estimate is calculated using Greenwood's variance.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive high-dose melphalan IV on day -1. PBSCs are reinfused on day 0. G-CSF is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive high-dose busulfan IV every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBSCs are reinfused on day 0 and G-CSF is administered IV or SC daily until blood counts recover.\n\nfilgrastim\n\nrecombinant interferon alfa\n\nbusulfan\n\ncyclophosphamide\n\nmelphalan\n\npamidronate disodium\n\nthalidomide\n\nperipheral blood stem cell transplantation","id":"OG000","title":"HD Chemo Followed by PBPC Rescue"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.","title":"Three-year Overall Survival","type":"PRIMARY","unitOfMeasure":"proportion of participants"}